Business Context and Reporting Period
This Form 8-K Current Report from Keros Therapeutics, Inc. (KROS) covers events occurring on August 6, 2025. The filing details significant executive leadership changes, including the appointment of a new Chief Scientific Officer, the departure of the President and Chief Operating Officer, and a restructuring of the Board of Directors. The company is a Delaware corporation headquartered in Lexington, Massachusetts.
Key Financial Metrics and Compensation
This filing does not contain financial performance data such as revenue, profit, cash flow, or debt levels. It focuses exclusively on executive compensation and severance arrangements:
- Lorena Lerner (New CSO): Annual base salary of $425,000 with a target discretionary bonus of 40%.
- Esther Cho (SVP, General Counsel): Annual base salary of $460,000 with a target discretionary bonus of 40%.
- Christopher Rovaldi (Departing President/COO): Severance package includes nine months of base salary, COBRA coverage for up to nine months, acceleration of 19,800 unvested RSUs, and up to $10,000 for outplacement services.
- Jean-Jacques Bienaimé (New Board Chair): Additional annual cash retainer of $30,000.
Material Changes Versus Prior Period
The filing reports the following material organizational changes effective August 6, 2025 (with some roles effective August 18, 2025):
- Executive Appointments: Lorena Lerner appointed Chief Scientific Officer; Jasbir Seehra appointed President (in addition to CEO); Jean-Jacques Bienaimé appointed Chair of the Board.
- Executive Departures: Christopher Rovaldi ceased serving as President and Chief Operating Officer.
- Board Restructuring: Jasbir Seehra stepped down as Chair of the Board but remains a director.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, revenue outlook, or specific risk factors beyond standard employment contract terms. Key contractual contingencies include:
- Severance Triggers: Both Dr. Lerner and Ms. Cho are eligible for enhanced severance (12 months salary, 100% target bonus, and equity acceleration) if terminated without cause or resigning for good reason within 12 months of a change of control.
- Consulting Transition: Mr. Rovaldi will provide up to 20 hours of consulting services for three months post-departure, with additional hours billed at $425/hour.
- Regulatory Disclosure: The company updated its corporate presentation for investor meetings (Item 7.01), which is furnished but not deemed "filed" under the Exchange Act.
Investor Verification Checklist
- Verify the impact of the President/COO departure on ongoing clinical trial operations and strategic execution.
- Review the full text of the employment agreements (Exhibits 10.1 and 10.3) for specific definitions of "Cause" and "Good Reason."
- Confirm the vesting schedule and current value of the 19,800 RSUs accelerated for Mr. Rovaldi.
- Assess the strategic rationale for the Board Chair transition from Dr. Seehra to Mr. Bienaimé.
- Examine the updated corporate presentation (Exhibit 99.1) for any new clinical data or pipeline updates not included in this 8-K.